Lantern Pharma Inc (LTRN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.47M
Last updated: Nov 17, 2026 at 11:01 AM ET
Lantern Pharma Inc (LTRN) Competitors
The companies most similar to Lantern Pharma are Liminatus Pharma, Inc. Class A Common Stock (LIMN), CNS Pharmaceuticals (CNSP) and Processa Pharmaceuticals (PCSA). By market cap, Lantern Pharma ranks 7th of the 13 companies on this page; Tscan Therapeutics (TCRX) is the largest at $10.89M.
Peer Comparison
LTRN's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Lantern Pharma (LTRN) | $6.47M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Traws Pharma Inc (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Alaunos Therapeutics Inc (TCRT) | $6.86M | N/A | N/A | 0.0% | N/A | -25.0% | 0.00% |
| PharmaCyte Biotech Inc (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Aprea Therapeutics Inc (APRE) | $5.91M | N/A | N/A | 0.0% | N/A | -98.4% | 0.00% |
| Tscan Therapeutics Inc (TCRX) | $10.89M | N/A | 3.6x | 0.0% | -129.7% | -65.8% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Longeveron LLC (LGVN) | $8.40M | N/A | 5.9x | 0.0% | N/A | -9.2% | 0.00% |
| Peer median | $6.38M | N/A | 4.8x | 0.0% | -247.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Lantern Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California. | LIMN competitors |
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Traws Pharma Inc (TRAW) | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. | TRAW competitors |
| Alaunos Therapeutics Inc (TCRT) | Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring... | TCRT competitors |
| PharmaCyte Biotech Inc (PMCB) | PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United... | PMCB competitors |
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Aprea Therapeutics Inc (APRE) | Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor... | APRE competitors |
| Tscan Therapeutics Inc (TCRX) | Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor... | TCRX competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Longeveron LLC (LGVN) | Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. | LGVN competitors |
Frequently Asked Questions About LTRN
Who are Lantern Pharma's main competitors?
The companies most similar to Lantern Pharma include Liminatus Pharma, Inc. Class A Common Stock (LIMN), CNS Pharmaceuticals (CNSP), Processa Pharmaceuticals (PCSA), Tempest Therapeutics (TPST) and Traws Pharma (TRAW), listed from the closest match.
Who is Lantern Pharma's biggest competitor?
Tscan Therapeutics (TCRX) is the largest of the similar companies at $10.89M; Liminatus Pharma, Inc. Class A Common Stock (LIMN) is the closest match by business profile, size, sector and industry.
How does LTRN stock compare with its competitors?
LTRN's net margin is 0.0% against a peer median of 0.0%.
Which of Lantern Pharma's competitors pays a higher dividend?
Lantern Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Lantern Pharma bigger than its competitors?
No. Lantern Pharma is 7th by market cap among the 13 companies on this page; the largest is Tscan Therapeutics (TCRX) at $10.89M.
LTRN pages: Overview, Earnings, Forecast, Financials, Competitors